Literature DB >> 25445398

TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess.

Leila Idrissova1, Harmeet Malhi2, Nathan W Werneburg1, Nathan K LeBrasseur3, Steven F Bronk1, Christian Fingas1, Tamar Tchkonia3, Tamar Pirtskhalava3, Thomas A White3, Michael B Stout3, Petra Hirsova1, Anuradha Krishnan1, Christian Liedtke4, Christian Trautwein4, Niklas Finnberg5, Wafik S El-Deiry5, James L Kirkland3, Gregory J Gores6.   

Abstract

BACKGROUND & AIMS: Low-grade chronic inflammation is a cardinal feature of the metabolic syndrome, yet its pathogenesis is not well defined. The purpose of this study was to examine the role of TRAIL receptor (TR) signaling in the pathogenesis of obesity-associated inflammation using mice with the genetic deletion of TR.
METHODS: TR knockout (TR(-/-)) mice and their littermate wild-type (WT) mice were fed a diet high in saturated fat, cholesterol and fructose (FFC) or chow. Metabolic phenotyping, liver injury, and liver and adipose tissue inflammation were assessed. Chemotaxis and activation of mouse bone marrow-derived macrophages (BMDMϕ) was measured.
RESULTS: Genetic deletion of TR completely repressed weight gain, adiposity and insulin resistance in FFC-fed mice. Moreover, TR(-/-) mice suppressed steatohepatitis, with essentially normal serum ALT, hepatocyte apoptosis and liver triglyceride accumulation. Gene array data implicated inhibition of macrophage-associated hepatic inflammation in the absence of the TR. In keeping with this, there was diminished accumulation and activation of inflammatory macrophages in liver and adipose tissue. TR(-/-) BMDMϕ manifest reduced chemotaxis and diminished activation of nuclear factor-κ B signaling upon activation by palmitate and lipopolysaccharide.
CONCLUSIONS: These data advance the concept that macrophage-associated hepatic and adipose tissue inflammation of nutrient excess requires TR signaling.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lipoapoptosis; Macrophage activation; Metainflammation; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2014        PMID: 25445398      PMCID: PMC4404200          DOI: 10.1016/j.jhep.2014.11.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  38 in total

Review 1.  Characteristics and biological functions of TRAF6.

Authors:  Jun-ichiro Inoue; Jin Gohda; Taishin Akiyama
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

2.  DR5 knockout mice are compromised in radiation-induced apoptosis.

Authors:  Niklas Finnberg; Joshua J Gruber; Peiwen Fei; Dorothea Rudolph; Anka Bric; Seok-Hyun Kim; Timothy F Burns; Hope Ajuha; Robert Page; Gen Sheng Wu; Youhai Chen; W Gillies McKenna; Eric Bernhard; Scott Lowe; Tak Mak; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults.

Authors:  Jong Weon Choi; Jung Soo Song; Soo Hwan Pai
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

4.  Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.

Authors:  Harmeet Malhi; Fernando J Barreyro; Hajime Isomoto; Steven F Bronk; Gregory J Gores
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

Review 5.  The TRAIL apoptotic pathway in cancer onset, progression and therapy.

Authors:  Ricky W Johnstone; Ailsa J Frew; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2008-10       Impact factor: 60.716

Review 6.  Obesity, inflammation, and insulin resistance.

Authors:  Steven E Shoelson; Laura Herrero; Afia Naaz
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

Review 7.  New developments in adipogenesis.

Authors:  Martina I Lefterova; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2009-03-09       Impact factor: 12.015

8.  Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.

Authors:  Geoffrey C Farrell; Claire Z Larter; Jing Yun Hou; Rena H Zhang; Matthew M Yeh; Jacqueline Williams; Aileen dela Pena; Rona Francisco; Sarah R Osvath; John Brooling; Narcissus Teoh; Lisa M Sedger
Journal:  J Gastroenterol Hepatol       Date:  2008-02-15       Impact factor: 4.029

9.  Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance.

Authors:  Libin Liu; Dennis Brown; Mary McKee; Nathan K Lebrasseur; Dan Yang; Kenneth H Albrecht; Katya Ravid; Paul F Pilch
Journal:  Cell Metab       Date:  2008-10       Impact factor: 27.287

10.  Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.

Authors:  Rafal P Witek; W Carl Stone; F Gamze Karaca; Wing-Kin Syn; Thiago A Pereira; Kolade M Agboola; Alessia Omenetti; Youngmi Jung; Vanessa Teaberry; Steve S Choi; Cynthia D Guy; John Pollard; Peter Charlton; Anna Mae Diehl
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

View more
  42 in total

Review 1.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

2.  Deletion of endoplasmic reticulum stress-responsive co-chaperone p58IPK protects mice from diet-induced steatohepatitis.

Authors:  Harikrishna Bandla; Debanjali Dasgupta; Amy S Mauer; Barbora Nozickova; Swarup Kumar; Petra Hirsova; Rondell P Graham; Harmeet Malhi
Journal:  Hepatol Res       Date:  2018-02-09       Impact factor: 4.288

3.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

Review 4.  Liver inflammation and fibrosis.

Authors:  Yukinori Koyama; David A Brenner
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

5.  Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand.

Authors:  Nagamani Vunnam; Sophia Szymonski; Petra Hirsova; Gregory J Gores; Jonathan N Sachs; Benjamin J Hackel
Journal:  Biochemistry       Date:  2020-09-30       Impact factor: 3.162

Review 6.  Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Authors:  Thomas Greuter; Harmeet Malhi; Gregory J Gores; Vijay H Shah
Journal:  JCI Insight       Date:  2017-09-07

7.  Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.

Authors:  Amy S Mauer; Petra Hirsova; Jessica L Maiers; Vijay H Shah; Harmeet Malhi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-12-30       Impact factor: 4.052

8.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4-/- Mouse.

Authors:  Anuradha Krishnan; Tomohiro Katsumi; Maria E Guicciardi; Adiba I Azad; Nazli B Ozturk; Christy E Trussoni; Gregory J Gores
Journal:  Am J Pathol       Date:  2020-03-30       Impact factor: 4.307

9.  Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles.

Authors:  Vikas K Verma; Haiyang Li; Ruisi Wang; Petra Hirsova; Malek Mushref; Yaming Liu; Sheng Cao; Patricia C Contreras; Harmeet Malhi; Patrick S Kamath; Gregory J Gores; Vijay H Shah
Journal:  J Hepatol       Date:  2015-11-26       Impact factor: 25.083

10.  Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.

Authors:  Petra Hirsova; Samar H Ibrahim; Anuradha Krishnan; Vikas K Verma; Steven F Bronk; Nathan W Werneburg; Michael R Charlton; Vijay H Shah; Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2016-01-05       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.